Vonoprazan <i>versus</i> conventional proton pump inhibitor‐based triple therapy as first‐line treatment against <i>Helicobacter pylori</i> : A multicenter retrospective study in clinical practice

Abstract

Vonoprazan-based triple therapy is feasible, and has a higher rate for H. pylori eradication than conventional PPI as a first-line regimen.